Protocol Ledger

NCT03911505 · Phase III · ACTIVE NOT RECRUITING

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

Interventional Phase III clinical trial protocol NCT03911505 sponsored by Amicus Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-13 Enrollment: 21 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03911505
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)21 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03911505
Protocol FieldVerified Registry Value
NCT IdentifierNCT03911505
Consolidated Lead SponsorAmicus Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment21 participants (ACTUAL)
Registered Start Date2020-02-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI